Primary hemostasis: platelet link
The process begins at the moment of endothelial injury when subendothelial structures, primarily collagen, are exposed. Platelets respond to this with a series of sequential changes:
- Adhesion. Platelets bind directly to collagen via GP Ia receptors and indirectly via von Willebrand factor, which serves as a bridge to GP Ib receptors.
- Activation. Cells change shape from discoid to flattened, extending pseudopodia to increase contact area. The concentration of calcium ions ($Ca^{2+}$) inside the cytoplasm sharply increases.
- Degranulation. Activated platelets release the contents of their granules into the blood: potent stimulators ADP and serotonin. Concurrently, thromboxane A2 ($TxA_2$) is synthesized within them.
- Aggregation. The released mediators act on neighboring cells via a positive feedback loop. Under their influence, GP IIb/IIIa receptors change their spatial structure and begin to bind fibrinogen. Fibrinogen molecules bind platelets together, forming a primary aggregate.
Secondary hemostasis: coagulation cascade
Concurrently with aggregation, the clotting system is triggered. Its main task is to reinforce the loose platelet plug with strong fibrin strands. Most clotting factors are synthesized in the liver and circulate in the blood as inactive zymogens.
- Initiation (extrinsic pathway). Upon vascular trauma, blood contacts tissue factor (TF), which is normally sequestered in the subendothelium. This leads to the rapid activation of factor VII.
- Reaction cascade. The complex of active factor VIIa and TF activates factors IX and X. The process occurs on negatively charged cell membrane phospholipids and strictly requires the presence of calcium.
- Thrombin generation. Factor Xa converts prothrombin (factor II) into active thrombin (factor IIa).
- Final stage. Thrombin cleaves peptides from soluble fibrinogen, converting it into insoluble fibrin. Fibrin strands polymerize, permeate the thrombus, and entrap erythrocytes—thus forming the definitive red thrombus.
Natural anticoagulant mechanisms
To prevent the thrombus from spreading to healthy parts of the vessel, intact endothelium actively suppresses hemostasis. Endothelial cells synthesize two major inhibitors:
- Prostacyclin ($PGI_2$). Binds to platelet receptors, activates adenylate cyclase, and increases cAMP levels. This leads to a drop in intracellular calcium, causing GP IIb/IIIa receptors to lose their ability to bind fibrinogen.
- Nitric oxide (NO). Acts as an endothelial relaxing factor, inhibiting adhesion and aggregation.
Both substances not only inhibit platelet function but also cause vasodilation (blood vessel widening). Upon vessel wall injury, the synthesis of these protective factors drops, and the balance shifts toward thrombus formation.
Principles of pharmacological correction
Understanding the mechanisms of hemostasis allows for targeted intervention in pathological processes (bleeding or thrombosis):
- Prevention of thrombosis: antiplatelet agents (suppress platelet function) and anticoagulants (block plasma clotting factors) are used.
- Lysis of existing thrombi: thrombolytic drugs are used, which activate plasminogen, converting it into plasmin—an enzyme that dissolves fibrin.
- Stopping bleeding: agents that increase blood clotting or drugs that inhibit fibrinolysis are prescribed.
Briefly: answers to topical questions
What functions does thrombin perform in the hemostatic process?
Thrombin performs key functions in the coagulation cascade, cellular activation, and regulation of clotting.
- Platelet activation — acts as a potent aggregation inducer, stimulates degranulation, and promotes expression of GP IIb/IIIa receptors.
- Fibrin formation — converts soluble fibrinogen into insoluble fibrin, forming a fibrin clot.
- Activation of plasma factors — activates other blood coagulation factors.
- Regulation of clotting and fibrinolysis — participates in the activation of clotting inhibitors (in complex with thrombomodulin, activates protein C).
- Pro-inflammatory action — increases endothelial permeability, stimulates the release of mediators from mast cells, and promotes the generation of anaphylatoxin C5a.
What antithrombotic substances are synthesized by the intact endothelium?
The intact endothelium synthesizes a number of substances that prevent blood clotting and platelet aggregation, and stimulate fibrinolysis.
- Prostacyclin (PGI2) — a prostaglandin that inhibits platelet activation and aggregation.
- Nitric oxide (NO) — an endothelial relaxing factor that suppresses platelet adhesion and aggregation.
- Tissue plasminogen activator (t-PA) — triggers thrombus lysis by converting plasminogen to plasmin.
- Tissue factor pathway inhibitor — blocks the formation of the VIIa–TF–Ca²⁺ complex, preventing the activation of factors X and IX.
Which blood coagulation factors are vitamin K-dependent?
Vitamin K-dependent coagulation factors include:
- Factor II (prothrombin).
- Factor VII (proconvertin).
- Factor IX (Christmas factor).
- Factor X (Stuart–Prower factor).
Their functional activity requires γ-carboxylation, which is carried out with the participation of vitamin K. Proteins C and S are also vitamin K-dependent components of the anticoagulant system, but are not coagulation factors.
What natural anticoagulants circulate in blood plasma?
Natural anticoagulants include:
- Antithrombin III — a plasma protein that forms inactive complexes with serine proteases, including thrombin and factors IXa, Xa, and XIIa.
- Protein C — a vitamin K-dependent protein circulating in an inactive form; upon activation, it induces the degradation of factors VIIIa and Va.
- Protein S — a non-enzymatic cofactor of activated protein C.
- Tissue factor pathway inhibitor, $α_2$-macroglobulin, and $α_1$-antitrypsin — other natural coagulation inhibitors.
Remembering the role of the main mediators is simple: ADP and Thromboxane A2 act as the "gas pedal" for platelets (increasing calcium and causing aggregation), while Prostacyclin acts as the "brake pedal" (decreasing calcium and inhibiting aggregation).
Class and exam questions
What is the difference between arterial and venous thrombosis?
In arteries, due to high blood flow velocity, platelet aggregation predominates. In veins, blood flow is slow, so coagulation with the formation of fibrin thrombi dominates there.
What is the role of thrombin in hemostasis?
Thrombin performs two key functions: it converts soluble fibrinogen into insoluble fibrin strands and acts as a potent stimulator of platelet activation itself.
Why are clotting cofactors necessary?
Factors VIII and V are not enzymes. Upon activation by thrombin, they act as specific membrane receptors, accelerating the catalytic action of the cascade's enzymes a billion-fold.
What else to study on this topic
- Biosynthesis and intracellular signal transduction of thromboxane A2
- Mechanism of action of ADP via purinergic P2Y12 receptors
- The role of cell membrane phospholipids in the activation of factors IXa and Xa
- Physiological regulation of fibrinolysis: plasminogen and antiplasmins
- Pathophysiology of hemostatic disorders: causes of hemorrhages and thromboses
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Hemostasis and Thrombosis" and 5,304 more pages on the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs affecting hemostasis and thrombosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.